IP Verse

Betapharm Arzneimittel Gmbh opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Betapharm Arzneimittel Gmbh

Patent Number:
EP3626270
Title:
New Use
Applicant:
NOVARTIS AG
Opposition Date:
Jul 2, 2024
Patent Number:
EP3294283
Title:
Sacubitril-Valsartan Dosage Regimen For Treating Heart Failure
Applicant:
NOVARTIS AG
Opposition Date:
Dec 7, 2023
Patent Number:
EP2959894
Title:
S1P Receptor Modulators For Treating Multiple Sclerosis
Applicant:
NOVARTIS AG
Opposition Date:
Jul 12, 2023
Patent Number:
EP3461503
Title:
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring
Applicant:
BIOMARIN PHARMACEUTICAL INC.
Opposition Date:
Oct 28, 2022
Patent Number:
EP2545939
Title:
Methods Of Administering Tetrahydrobiopterin, Associated Compositions, And Methods Of Measuring
Applicant:
BIOMARIN PHARMACEUTICAL INC.
Opposition Date:
Sep 15, 2021
Patent Number:
EP2340828
Title:
Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor
Applicant:
NOVARTIS AG
Opposition Date:
Apr 15, 2021
Patent Number:
EP2493466
Title:
Novel Antitumoral Use Of Cabazitaxel
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Mar 31, 2021
Patent Number:
EP3395338
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Dec 9, 2020
Patent Number:
EP3395339
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Dec 9, 2020
Patent Number:
EP3260117
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN INC.
Opposition Date:
Nov 24, 2020

Competitors of Betapharm Arzneimittel Gmbh

NOVARTIS AG

AMGEN INC.

NOVARTIS PHARMA AG

Want to track Betapharm Arzneimittel Gmbh?

Feel free to send us a message here and we will get back to you